Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen

類似資料

• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
  著者:: Dowsett, M, 等
  出版事項: (2009)
• Variation in use of adjuvant tamoxifen.
  著者:: Davies, C, 等
  出版事項: (1998)
• Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
  著者:: Butani D, 等
  出版事項: (2021-11-01)
• Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
  著者:: Gelber, R, 等
  出版事項: (1996)
• Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
  著者:: Ingle, J, 等
  出版事項: (2009)